GB2371622A - Susceptibility gene for inflammatory bowel disease - Google Patents
Susceptibility gene for inflammatory bowel disease Download PDFInfo
- Publication number
- GB2371622A GB2371622A GB0206993A GB0206993A GB2371622A GB 2371622 A GB2371622 A GB 2371622A GB 0206993 A GB0206993 A GB 0206993A GB 0206993 A GB0206993 A GB 0206993A GB 2371622 A GB2371622 A GB 2371622A
- Authority
- GB
- United Kingdom
- Prior art keywords
- ibd
- inflammatory bowel
- disease
- bowel disease
- ulcerative colitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000022559 Inflammatory bowel disease Diseases 0.000 title abstract description 11
- 108090000623 proteins and genes Proteins 0.000 title abstract description 4
- 206010009900 Colitis ulcerative Diseases 0.000 abstract description 4
- 208000011231 Crohn disease Diseases 0.000 abstract description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 4
- 108700028369 Alleles Proteins 0.000 abstract description 2
- 108700011778 CCR5 Proteins 0.000 abstract description 2
- 238000012217 deletion Methods 0.000 abstract description 2
- 230000037430 deletion Effects 0.000 abstract description 2
- 238000001514 detection method Methods 0.000 abstract description 2
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 238000012216 screening Methods 0.000 abstract description 2
- 229940124597 therapeutic agent Drugs 0.000 abstract description 2
- 241000764238 Isis Species 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
An association between a 32bp deletion in the human gene encoding chemokine receptor CCR5 and the development of inflammatory bowel disease. (IBD), in particular Crohn's disease and ulcerative colitis is described. Methods of diagnosis of susceptibility to IBD and of distinguishing between Crohn's disease and ulcerative colitis are provided which involve detection of the CCR5- W 32 allele in patients suffering from, or suspected of developing. IBD. Screening methods suitable for identifying molecules with potential as therapeutic agents against IBD are also described.
Description
,,UK Patent Application, g,GB.,2 371 622 {13JA (43) Date of Printing by UK
Office 31.07.2002 (21) Application No 0206993.8 (51) INTCL7 C12Q 1/68, GOlN 33/50 // A61K 39/00 (22) Date of Filing 23.09.1999 (52) UK CL (Edition T) (86) International Application Data G1B BAC B223 PCT/GBg9/03192 En 23.09.1999 U1S S1318 (87) International Publication Data (56) Documents Cited by ISA WO01/21832 En 29.03.2001 WO 99/32100 A WO 98/34945 A Gastroenterology, April l999r Vol. 116, No. 4, page (71) Applicant(s) a821 Isis Innovation Limited Nature, 1996, Vol. 382, No. 6593, pages 722-725 llacorPorated in the Umted Kingdoml Ewert House, Ewert Place, Summertown, OXFORD, (58) Field of Search by ISA
OX2 7BZ, United Kingdom INT CL7 A61K, C12Q, GOlN EPO-lntemal, WPI Data, PAJ, MEDLINE, BIOSIS (72) Inventor(s) EMBASE, CHEM ABS Data Derek Parry Jewell Jon David Simmons Jack Satsangi 174) Agent and/or Address for Service Kenneth lan Welsh Boult Wade Tennant Lee R Brettman Vsrulam Gardens, 70 Gray's Inn Road, LONDON, WC1X 8BT, United Kingdom (54) Abstract Title Susceptibility gene for inflammatory bowel disease (57) An association between a 32bp deletion in the human gene encoding chemokine receptor CCR5 and the development of inflammatory bowel disease. (iBD), in particular Crohn's disease and ulcerative colitis is described. Methods of diagnosis of susceptibility to IBD and of distinguishing between Crohn's disease and ulcerative colitis are provided which involve detection of the CCR5-Q32 allele in patients suffering from, or suspected of developing, IBD. Screening methods suitable for identifying molecules with potential as therapeutic agents against IBD are also described.
G) W CD D
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB1999/003192 WO2001021832A1 (en) | 1999-09-23 | 1999-09-23 | Susceptibility gene for inflammatory bowel disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB0206993D0 GB0206993D0 (en) | 2002-05-08 |
| GB2371622A true GB2371622A (en) | 2002-07-31 |
Family
ID=10847634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB0206993A Withdrawn GB2371622A (en) | 1999-09-23 | 1999-09-23 | Susceptibility gene for inflammatory bowel disease |
Country Status (4)
| Country | Link |
|---|---|
| AU (1) | AU6104699A (en) |
| CA (1) | CA2385381A1 (en) |
| GB (1) | GB2371622A (en) |
| WO (1) | WO2001021832A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101943311B (en) * | 2010-08-23 | 2012-12-26 | 广东爵仕泳池水疗设备有限公司 | Multifunctional TV mount |
| RU2563172C1 (en) * | 2014-11-12 | 2015-09-20 | Общество с ограниченной ответственностью "Покровский банк стволовых клеток" | METHOD FOR DETERMINING CCR5 delta 32 ALLELE POLYMORPHISM |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997032019A2 (en) * | 1996-03-01 | 1997-09-04 | Euroscreen S.A. | C-c ckr-5, cc-chemikines receptor, derivatives thereof and their uses |
| WO1998005798A1 (en) * | 1996-08-08 | 1998-02-12 | The Aaron Diamond Aids Research Center | Hiv coreceptor mutants |
| WO1998034945A1 (en) * | 1997-02-06 | 1998-08-13 | Epoch Pharmaceuticals, Inc. | Targeted modification of the ccr-5 gene |
| WO1999032100A2 (en) * | 1997-12-19 | 1999-07-01 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative |
-
1999
- 1999-09-23 CA CA002385381A patent/CA2385381A1/en not_active Abandoned
- 1999-09-23 GB GB0206993A patent/GB2371622A/en not_active Withdrawn
- 1999-09-23 WO PCT/GB1999/003192 patent/WO2001021832A1/en not_active Ceased
- 1999-09-23 AU AU61046/99A patent/AU6104699A/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997032019A2 (en) * | 1996-03-01 | 1997-09-04 | Euroscreen S.A. | C-c ckr-5, cc-chemikines receptor, derivatives thereof and their uses |
| WO1998005798A1 (en) * | 1996-08-08 | 1998-02-12 | The Aaron Diamond Aids Research Center | Hiv coreceptor mutants |
| WO1998034945A1 (en) * | 1997-02-06 | 1998-08-13 | Epoch Pharmaceuticals, Inc. | Targeted modification of the ccr-5 gene |
| WO1999032100A2 (en) * | 1997-12-19 | 1999-07-01 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative |
Non-Patent Citations (2)
| Title |
|---|
| Gastroenterology, April 1999, Vol. 116, No. 4, page a821 * |
| Nature, 1996, Vol. 382, No. 6593, pages 722-725 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU6104699A (en) | 2001-04-24 |
| WO2001021832A1 (en) | 2001-03-29 |
| GB0206993D0 (en) | 2002-05-08 |
| CA2385381A1 (en) | 2001-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hoffmeyer et al. | Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo | |
| Robertson et al. | Occurrence of Cryptosporidium oocysts and Giardia cysts in sewage in Norway | |
| Jin et al. | Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4* 1B and 3A5* 3 for 25 fentanyl cases | |
| Pang et al. | The hepatitis C viral NS3 protein is a processive DNA helicase with cofactor enhanced RNA unwinding | |
| Rogel et al. | Adenylate cyclase toxin from Bordetella pertussis. The relationship between induction of cAMP and hemolysis. | |
| Yang et al. | Siderophore production by Pseudomonas pseudomallei | |
| Conway et al. | The Roles of Valine 208 and Histidine 211 in Ligand Binding and Receptor Function of the Ovine Mel1aβMelatonin Receptor | |
| Ettinger et al. | Allelic variation in key peptide-binding pockets discriminates between closely related diabetes-protective and diabetes-susceptible HLA-DQB1* 06 alleles | |
| Paul et al. | Production of extracellular nucleic acids by genetically altered bacteria in aquatic-environment microcosms | |
| Lombard et al. | HLA class II disease associations in southern Africa | |
| Karl et al. | Localization, transmission, spontaneous mutations, and variation of function of the Dpp4 (Dipeptidyl-peptidase IV; CD26) gene in rats | |
| Xu et al. | Evidence for the effect of gender on activity of (S)-mephenytoin 4’-hydroxylase (CYP2C19) in a Chinese population | |
| King et al. | Coeliac disease: investigation of proposed causal variants in the CTLA4 gene region | |
| Kidsley et al. | Genomic analysis of fluoroquinolone-susceptible phylogenetic group B2 extraintestinal pathogenic Escherichia coli causing infections in cats | |
| Shimoda et al. | Lack of impact of CYP1A2 genetic polymorphism (C/A polymorphism at position 734 in intron 1 and G/A polymorphism at position− 2964 in the 5′-flanking region of CYP1A2) on the plasma concentration of haloperidol in smoking male Japanese with schizophrenia | |
| Wiencke et al. | Primary sclerosing cholangitis is associated with extended HLA‐DR3 and HLA‐DR6 haplotypes | |
| GB2371622A (en) | Susceptibility gene for inflammatory bowel disease | |
| Horton et al. | Reciprocal cross-resistance in human rhabdomyosarcomas selected in vivo for primary resistance to vincristine and L-phenylalanine mustard | |
| Ebeli-Struijk et al. | The distribution of esterase D variants in different ethnic groups | |
| NZ309777A (en) | Method for the detection of compounds that modulate the effects of the obese protein | |
| Marchant et al. | A selective inhibitor of N8-acetylspermidine deacetylation in mice and HeLa cells without effects on histone deacetylation | |
| Wucherpfennig | MHC‐linked susceptibility to type 1 diabetes: a structural perspective | |
| Garcia‐Ramos et al. | HLA class II genotypes in Mexican Mestizo patients with myasthenia gravis | |
| Velickovic et al. | HLA‐DRB1 and HLA‐DQB1 polymorphisms in Pacific Islands populations | |
| Giardina et al. | Mapping the future of common diseases: lessons from psoriasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |